Immune checkpoint blockage using monoclonal antibodies against PD-1 and its main ligand PD-L1 has substantially improved the treatment landscape of advanced-stage NSCLC and made its most strong impact in the stage III and first-line stage IV settings [175,176,177,178]. Here, PDCD1 is linked to non-small cell lung carcinoma.